Trial Profile

Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Tofacitinib (Primary) ; Azathioprine; Methotrexate; Methotrexate; Mycophenolate mofetil; Rituximab
Indications Granulomatosis with polyangiitis
Focus Therapeutic Use
Acronyms SATELITE

Most Recent Events

03 Feb 2025 Given protocol has been amended as above-1) Phase has been changed from 2 to 3. 2) Treatment part has been amended (Tofacitinib has been added and removed abatacept).
03 Feb 2025 Planned End Date changed from 1 Jan 2027 to 1 Jan 2029.
03 Feb 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Sep 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com